Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib

NCT01775553 is registered in ClinicalTrials.gov with Ajai Chari as lead sponsor.

NCT NCT01775553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01775553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
Lead sponsor
Ajai Chari
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
May 31, 2016
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma, relapse multiple myeloma